Updated Jul 16, 2026 · Last SEC filing 2026-07-06
Intellia Therapeutics, Inc. (NTLA) has filed 9 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-06. 6 Form 8-K material event filings were reported by NTLA in the last 90 days. 1 Form 144 notices of proposed sale were filed for NTLA stock. InsiderAlpha tracks every NTLA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | In Vitro & In Vivo Diagnostic Substances (SIC 2835) |
|---|---|
| SEC CIK | 0001652130 |
| Form 4 filings (90d) | 9 |
|---|---|
| Form 8-K filings (90d) | 6 |
| Form 144 notices (90d) | 1 |
| Latest Form 4 filing | 2026-07-06 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dulac Edward J III | EVP, Chief Financial Officer | S — Open-market sale | 4.7K | $18.00 | $84K | SEC | |
| Dube Michael P | VP, Chief Accounting Officer | S — Open-market sale | 2.6K | $16.78 | $44K | SEC | |
| Keresty Georgia | Insider | A — Grant or award | 9.2K | $0.00 | — | SEC | |
| CHASE WILLIAM J | Insider | A — Grant or award | 9.2K | $0.00 | — | SEC | |
| Goff Brian | Insider | A — Grant or award | 9.2K | $0.00 | — | SEC | |
| GOODMAN JESSE | Insider | A — Grant or award | 9.2K | $0.00 | — | SEC | |
| Verwiel Frank | Insider | A — Grant or award | 9.2K | $0.00 | — | SEC | |
| Cohen Fred E | Insider | A — Grant or award | 9.2K | $0.00 | — | SEC | |
| Bhanji Muna | Insider | A — Grant or award | 9.2K | $0.00 | — | SEC | |
| Clark Eliana | EVP, Chief Technical Officer | S — Open-market sale | 607 | $13.78 | $8K | SEC | |
| BASTA JAMES | EVP, General Counsel | S — Open-market sale | 1.2K | $13.78 | $17K | SEC | |
| Dulac Edward J III | EVP, Chief Financial Officer | A — Grant or award | 61.3K | $0.00 | — | SEC | |
| LEONARD JOHN M | President and CEO | A — Grant or award | 156.4K | $0.00 | — | SEC | |
| Lebwohl David | EVP, Chief Medical Officer | A — Grant or award | 9.9K | $0.00 | — | SEC | |
| Schultes Birgit C | EVP, Chief Scientific Officer | A — Grant or award | 39.2K | $0.00 | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Intellia Therapeutics, Inc. (NTLA). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| CHASE WILLIAM J | 2 | — |
| Verwiel Frank | 2 | — |
| Keresty Georgia | 2 | — |
| Goff Brian | 2 | — |
| GOODMAN JESSE | 2 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in NTLA insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live NTLA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.